Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH

Sagimet Biosciences Inc.

Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.
PK data support further development; no drug-drug interaction signals observed; no treatment discontinuations.
Company plans Phase 2 proof-of-concept trial in MASH F4 fibrosis patients in 2H 2026 pending regulatory consultation.
Global license agreement with TAPI (TEVA affiliate) to develop once-daily fixed-dose combination tablet for Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.